We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
-1.7%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$170M
AUM Growth
-$2.53M
Cap. Flow
+$6.01M
Cap. Flow %
3.53%
Top 10 Hldgs %
52.61%
Holding
53
New
12
Increased
19
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
STRM
Streamline Health Solutions
STRM
+$7.38M
2
ALKS icon
Alkermes
ALKS
+$5.2M
3
CVS icon
CVS Health
CVS
+$4.95M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.65M
5
COLL icon
Collegium Pharmaceutical
COLL
+$3.53M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$12.1M
2
UTHR icon
United Therapeutics
UTHR
+$7.07M
3
LH icon
Labcorp
LH
+$5.86M
4
AMGN icon
Amgen
AMGN
+$5.84M
5
MRK icon
Merck
MRK
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 96.1%
2 Consumer Staples 2.06%
3 Technology 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOH icon
26
Molina Healthcare
MOH
$10.4B
$1.98M 1.16%
+6,000
New +$1.93M
IQV icon
27
IQVIA
IQV
$40.7B
$1.81M 1.06%
+10,000
New +$2.19M
TCMD icon
28
Tactile Systems Technology
TCMD
$618M
$1.75M 1.03%
225,000
+50,000
+29% +$417K
PLXS icon
29
Plexus
PLXS
$6.43B
$1.75M 1.03%
20,000
+14,000
+233% +$1.25M
ASND icon
30
Ascendis Pharma A/S
ASND
$16.5B
$1.55M 0.91%
15,000
– –
FENC icon
31
Fennec Pharmaceuticals
FENC
$335M
$1.42M 0.83%
+175,000
New +$1.2M
RDNT icon
32
RadNet
RDNT
$4.98B
$1.22M 0.72%
60,000
+10,000
+20% +$202K
ISEE
33
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$897K 0.53%
50,000
-150,000
-75% -$1.97M
SLGC
34
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$870K 0.51%
300,000
-50,000
-14% -$210K
BIO icon
35
Bio-Rad Laboratories Class A
BIO
$8.76B
$834K 0.49%
+2,000
New +$997K
NVST icon
36
Envista
NVST
$4.62B
$820K 0.48%
+25,000
New +$947K
DMTK
37
DELISTED
DermTech, Inc. Common Stock
DMTK
$693K 0.41%
175,000
+75,000
+75% +$461K
BDX icon
38
PUT
Becton Dickinson
BDX
$46.4B
$680K 0.4%
+200
New +$49.8K
MXCT icon
39
MaxCyte
MXCT
$108M
$534K 0.31%
+82,099
New +$458K
CDNA icon
40
CareDx
CDNA
$1.83B
$426K 0.25%
25,000
– –
VRAY
41
DELISTED
ViewRay, Inc.
VRAY
$364K 0.21%
100,000
-300,000
-75% -$1.01M
SPY icon
42
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$125K 0.07%
+2,500
New +$993K
OEF icon
43
CALL
iShares S&P 100 ETF
OEF
$19.5B
$76K 0.04%
4,000
+1,500
+60% +$272K
VTRS icon
44
CALL
Viatris
VTRS
$20.8B
$30K 0.02%
+4,000
New +$39.4K
SLGCW
45
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$9K 0.01%
20,000
– –
AMGN icon
46
Amgen
AMGN
$209B
– –
-24,000
Closed -$5.84M
GLD icon
47
CALL
SPDR Gold Trust
GLD
$131B
– –
-1,500
Closed -$288K
INMD icon
48
InMode
INMD
$871M
– –
-50,000
Closed -$1.12M
LH icon
49
Labcorp
LH
$25.2B
– –
-29,100
Closed -$5.86M
UTHR icon
50
United Therapeutics
UTHR
$26.1B
– –
-30,000
Closed -$7.07M
1
2
3

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q3 2022 Portfolio in Review

As of Q3 2022, Tamarack Advisers held 53 positions worth $170M, down 1.5% from $173M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Tamarack Advisers deployed $6.01M of net new capital in Q3 2022, opening 12 new positions and adding to 19 existing holdings. Its largest new stake was Streamline Health Solutions: 328,725 shares worth $5.87M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Cigna, an estimated $12.1M trimmed.

  • Tamarack Advisers's largest Q3 2022 buy was Streamline Health Solutions: 328,725 shares worth $5.87M.
  • Tamarack Advisers added most to BioMarin Pharmaceuticals in Q3 2022, an estimated $3.65M increase.
  • Tamarack Advisers's biggest Q3 2022 reduction was Cigna, cutting an estimated $12.1M.
  • Tamarack Advisers fully exited United Therapeutics in Q3 2022, selling an estimated $7.07M.
  • Tamarack Advisers's ten largest holdings make up 53% of its $170M portfolio in Q3 2022.
  • Tamarack Advisers opened 12 new positions and closed 7 in Q3 2022.
  • Tamarack Advisers's portfolio value fell 1.5% quarter-over-quarter to $170M.

Based on Tamarack Advisers's 13F filing for Q3 2022, filed 15 Nov 2022.